FindTrial
Sign In

To study the Yogvahi action of Rasasindoor with Eclipta alba(Bhringraj) in management of essential B.P.

Clinical study to evaluate the Yogvahi action of Rasasindoor with aqueous extract of Eclipta alba in management of Essential Hypertension

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/02/040309
Enrollment
100
Registered
2022-02-15
Start date
Unknown
Completion date
Unknown
Last updated
2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I10- Essential (primary) hypertension

Interventions

None listed

Sponsors

SHRI KRISHNA AYUSH UNIVERSITY KURUKSHETRA
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients who already diagnosed as E.H.T will be selected. 2.Patients with Stage 1 Hypertension(having systolic B.P. upto 160 and diastolic B.P. upto 100 )will be selected for the study. 3.Patients willing to give written inform consent to participate in the study

Exclusion criteria

Exclusion criteria: 1.Essential hypertension with any complications. Renal diseases, Diabetic mellitus 2.Pregnancy induced hypertension. 3.Patients using drugs like oral contraceptive pills, steroids. 4.Ventricular hypertrophy, secondary hypertension, coarctation of aorta. Portal hypertension 5.Renal artery stenosis induced hypertension 6.Patients who enroll in some other clinical trial.

Design outcomes

Primary

MeasureTime frame
To rule out the significant result of Rasasindoor with Aqueous extract of Eclipta alba in management of Essential Hypertension.Timepoint: 4 Weeks—

Secondary

MeasureTime frame
Change in lab parametrs from baseline.Timepoint: 4 weeks—

Countries

India

Contacts

Public ContactProf Balbir Singh

Shri Krishna Ayush University Kurukshetra

balbirsandhu63@gmail.com9813063424

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026